M Yamano

Summary

Affiliation: Yamanouchi Pharmaceutical Co
Country: Japan

Publications

  1. ncbi request reprint Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice
    M Yamano
    Applied Pharmacology Research, Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co Ltd, Tsukuba, Japan
    J Pharmacol Exp Ther 292:181-7. 2000
  2. ncbi request reprint Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo
    A Nishida
    Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co Ltd, Ibaraki, Japan
    J Pharmacol Exp Ther 269:725-31. 1994
  3. ncbi request reprint Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation
    K Miyata
    Neuroscience and Gastrointestinal Research Laboratories, Yamanouchi Pharmaceutical Co Ltd, Ibaraki, Japan
    Eur J Pharmacol 250:303-10. 1993
  4. ncbi request reprint YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats
    A Nishida
    Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co, Ltd, Tsukuba, Japan
    J Pharmacol Exp Ther 270:1256-61. 1994
  5. doi request reprint Influence of gastric acid on gastric emptying and gastric distension-induced pain response in rats--effects of famotidine and mosapride
    Y Keto
    Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc, Tsukuba, Ibaraki, Japan
    Neurogastroenterol Motil 24:147-53, e88. 2012
  6. ncbi request reprint Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro
    H Ito
    Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co, Ltd, 21 Miyukigaoka, Tsukuba, Ibaraki 305 8585, Japan
    Eur J Pharmacol 409:195-201. 2000
  7. ncbi request reprint Protective effects of a PAF receptor antagonist and a neutrophil elastase inhibitor on multiple organ failure induced by cerulein plus lipopolysaccharide in rats
    M Yamano
    Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co Ltd, Tsukuba, Ibaraki, Japan
    Naunyn Schmiedebergs Arch Pharmacol 358:253-63. 1998

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice
    M Yamano
    Applied Pharmacology Research, Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co Ltd, Tsukuba, Japan
    J Pharmacol Exp Ther 292:181-7. 2000
    ..The results also suggest that activation of corticotropin-releasing hormone receptors is involved in IFN-alpha-induced depression-like behavior, but the prostaglandin and opioid systems do not participate in this process...
  2. ncbi request reprint Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo
    A Nishida
    Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co Ltd, Ibaraki, Japan
    J Pharmacol Exp Ther 269:725-31. 1994
    ..v. L-365,260 (1-10 mumol/kg i.v.) and Cl-988 (0.3-3 mumol/kg i.v.) also antagonized acid secretion induced by pentagastrin, with ED50 values of 4.23 and 1.01 mumol/kg, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)..
  3. ncbi request reprint Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation
    K Miyata
    Neuroscience and Gastrointestinal Research Laboratories, Yamanouchi Pharmaceutical Co Ltd, Ibaraki, Japan
    Eur J Pharmacol 250:303-10. 1993
    ..Thus, YM114 is a potent and stereoselective 5-HT3 receptor antagonist with much greater protective effects against stress-induced defecation than trimebutine...
  4. ncbi request reprint YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats
    A Nishida
    Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co, Ltd, Tsukuba, Japan
    J Pharmacol Exp Ther 270:1256-61. 1994
    ..These results suggest that YM022 possesses antisecretory and antiulcer activities that are as potent as those of famotidine in rats and that YM022 represents a useful therapeutic agent in the treatment of peptic ulcer disease...
  5. doi request reprint Influence of gastric acid on gastric emptying and gastric distension-induced pain response in rats--effects of famotidine and mosapride
    Y Keto
    Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc, Tsukuba, Ibaraki, Japan
    Neurogastroenterol Motil 24:147-53, e88. 2012
    ..Delayed gastric emptying and hypersensitivity to gastric distension (GD) contribute importantly to the pathophysiology of FD...
  6. ncbi request reprint Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro
    H Ito
    Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co, Ltd, 21 Miyukigaoka, Tsukuba, Ibaraki 305 8585, Japan
    Eur J Pharmacol 409:195-201. 2000
    ..These results suggest that YM-31636 is a potent and selective 5-HT3 receptor agonist, preferentially acting on the contraction of the colon...
  7. ncbi request reprint Protective effects of a PAF receptor antagonist and a neutrophil elastase inhibitor on multiple organ failure induced by cerulein plus lipopolysaccharide in rats
    M Yamano
    Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co Ltd, Tsukuba, Ibaraki, Japan
    Naunyn Schmiedebergs Arch Pharmacol 358:253-63. 1998
    ..These results in the present model are largely consistent with those in patients with MOF, indicating that this model is suited for MOF in humans and may be used as a model to test new therapeutic approaches...